Natera Inc. a leading entity in the realm of cell-free DNA and genetic testing, has achieved another significant breakthrough as its Prospera Lung test has obtained Medicare coverage under the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Services (MolDX) Program. This development marks a substantial milestone for single lung transplant (SLT) recipients in the United States. The coverage is specifically applicable to SLT patients who require regular surveillance post-transplant, representing about 20% of all U.S. lung transplantation cases.
The Prospera Lung test is specifically designed to aid in the monitoring and early detection of potential organ rejection in lung transplant recipients. Through leveraging advanced technology in cell-free DNA, Natera has positioned itself as a prominent figure capable of transforming post-transplant care, potentially reducing the risk of complications and improving patient outcomes. The CMS MolDX Program’s endorsement of the test signifies a seal of approval for not just meeting stringent clinical utility requirements but for aligning with necessary safety standards.
Natera’s commitment to innovation and advancing medical technology is further underscored by its other recent achievements. The company recently announced that its Co-Founder and Natera Inc. a leading entity in the realm of cell-free DNA and genetic testing, has achieved another significant breakthrough as its Prospera Lung test has obtained Medicare coverage under the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Services (MolDX) Program. This development marks a substantial milestone for single lung transplant (SLT) recipients in the United States. The coverage is specifically applicable to SLT patients who require regular surveillance post-transplant, representing about 20% of all U.S. lung transplantation cases. Executive Chairman, Matthew Rabinowitz, PhD, has been bestowed the
Comments